Alimba, Darwin O.
HRN: 22-81-52 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/02/2023
CO-AMOXICLAV 625MG (TAB)
04/02/2023
04/09/2023
PO
625mg
TID
Non Healing Wound
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes